192 related articles for article (PubMed ID: 16167046)
1. Systemic therapeutic strategies for prostate cancer.
Nelson WG
Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
[No Abstract] [Full Text] [Related]
2. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.
Carducci MA; Carroll PR
Urology; 2005 May; 65(5 Suppl):18-22; discussion 22. PubMed ID: 15885275
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of bone metastases: therapeutic strategies in 2003].
Paule B
Prog Urol; 2003 Apr; 13(2 Suppl 1):36-47. PubMed ID: 12815808
[No Abstract] [Full Text] [Related]
4. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
[TBL] [Abstract][Full Text] [Related]
5. [Review of phase III clinical trials on combined anti-androgen therapies in patients with metastasized prostatic cancer].
Denis L; Dalesio O; Murphy G
Prog Urol; 1993 Feb; 3(1):75-85. PubMed ID: 8485599
[No Abstract] [Full Text] [Related]
6. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
7. The association between measures of progression and survival in castrate-metastatic prostate cancer.
Scher HI; Warren M; Heller G
Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
[TBL] [Abstract][Full Text] [Related]
8. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
Duchesne GM; Syme R; Howell D
J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
[No Abstract] [Full Text] [Related]
9. [Metastatic cancer of the prostate: course, diagnosis and therapeutic management].
Wisard M; Gabellon S
Rev Med Suisse Romande; 1995 Mar; 115(3):241-7. PubMed ID: 7777765
[No Abstract] [Full Text] [Related]
10. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.
Ryan CJ; Small EJ
J Clin Oncol; 2005 Nov; 23(32):8225-31. PubMed ID: 16278477
[TBL] [Abstract][Full Text] [Related]
11. What to do if prostate cancer returns.
Johns Hopkins Med Lett Health After 50; 2001 Dec; 13(10):6-7. PubMed ID: 11727445
[No Abstract] [Full Text] [Related]
12. [Hormonal treatment of cancer of the prostate: review and present status].
Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
[No Abstract] [Full Text] [Related]
13. The role of bisphosphonates in the treatment of prostate cancer.
Parker CC
BJU Int; 2005 May; 95(7):935-8. PubMed ID: 15839907
[No Abstract] [Full Text] [Related]
14. [The study landscape for prostate cancer].
Miller K
Urologe A; 2005 Dec; 44(12):1431-4. PubMed ID: 16292461
[TBL] [Abstract][Full Text] [Related]
15. Rising prostate-specific antigen after primary prostate cancer therapy.
Ward JF; Moul JW
Nat Clin Pract Urol; 2005 Apr; 2(4):174-82. PubMed ID: 16474760
[TBL] [Abstract][Full Text] [Related]
16. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
Ohlson N; Bergh A; Nygren K; Stattin P; Wikström P
Eur Urol; 2006 Apr; 49(4):675-83. PubMed ID: 16387414
[TBL] [Abstract][Full Text] [Related]
17. High risk biochemical relapse and the timing of androgen deprivation therapy.
Ryan CJ; Small EJ
J Urol; 2006 Dec; 176(6 Pt 2):S61-5. PubMed ID: 17084171
[TBL] [Abstract][Full Text] [Related]
18. Management of high risk metastatic prostate cancer: the case for novel therapies.
Brand TC; Tolcher AW
J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
[TBL] [Abstract][Full Text] [Related]
19. Natural history and treatment of bone complications in prostate cancer.
Saad F; Clarke N; Colombel M
Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
[TBL] [Abstract][Full Text] [Related]
20. What to do when prostate cancer returns.
Johns Hopkins Med Lett Health After 50; 2003 Jan; 14(11):6. PubMed ID: 12532917
[No Abstract] [Full Text] [Related]
[Next] [New Search]
